176 results about "Placenta size" patented technology

The present invention relates to ocular plugs formed from a biodegradable material. The plugs comprises a shaft and, optionally, a cap. The ocular plugs are intended to occlude, and to repair, discontinuities in the sclera, whether formed deliberately during injection or surgical foray into the eye, or accidentally. The method further provides methods of making the ocular plug. the invention also provides methods of using the ocular plugs to occlude and repair discontinuities in the sclera, or to deliver biologically active compounds to the sclera or the eye. Finally, the invention provides kits comprising one or more ocular plugs in a container.

The present invention provides methods for culturing, expanding and differentiating stem cells, particularly human embryonic stem cells. The methods comprise culturing the stem cells for a period of time on a collagen biofabric, particularly a collagen biofabric derived from the amniotic membrane, chorion, or both, from mammalian placenta.

The present invention provides an improved kit for the collection of umbilical cord blood and placental blood, and collection of the placenta from which such blood is obtained. The kit improves upon existing kits in that it provides for improved user convenience, provides for the collection of the placenta itself, and better maintains the internal temperature of the container in which the collected blood and placenta are shipped to a blood bank or registry. The invention further provides a method of collecting umbilical cord and placental blood, and the placenta from which such blood is obtained, comprising using the kit described herein.

A device is provided for blood extraction and collection from the placenta and/or the umbilical cord through a system that combines the collection of the blood falling under gravity, together with a suction system facilitating this fall. Thus, a larger amount of blood can be extracted than is obtained by conventional gravity systems without posing a health risk to the mother, allowing a controlled suction that prevents premature detachment of the placenta.

The invention relates to a method for separating and extracting stem cells from a placenta, umbilical cord or adipose tissue, which comprises the following process steps: firstly mixing the placenta, umbilical cord or adipose tissue and a cell maintenance fluid according to the proportion by weight of 2.5-4:1, putting the mixture into a tissue crushing barrel, adding collagenase after crushing, uniformly mixing, hatching at the temperature of 37 DEG C, filtering, adding a precipitator, sucking a supernatant fluid after settling, centrifuging, removing the supernatant fluid, adding concentrated cells into a liquid of diatrizoate sodium-ficoll 400#, then centrifuging, collecting 10-15 ml of intermediate cell layer, washing with the cell maintenance fluid, counting the collected cells, and providing the cells for clinical use when the cell survival ratio is more than or equal to 95 percent. The invention not only realizes the separation and the extraction of all stem cells from the placenta, umbilical cord or adipose tissue, but also realizes industrialized production, and enables doctors to conveniently, safely and canonically obtain the adult stem cells in clinic and use the adult stem cells for treating the diseases of patients as using medicaments, thereby solving the bottleneck problem of difficult obtainment of adult stem cells in clinic and popularizing a cell treatment technology.

The invention relates to a method for separating mesenchymal stem cells from placenta. The method comprises the following steps: (a) taking placental cotyledon, and fully washing by using a phosphate buffer solution (PBS) to remove residual blood from the placenta; (b) cutting the placental cotyledon into blocks, adding a PBS containing tissue digestive enzyme, and incubating and digesting at 37DEG C; (c) filtering the tissue blocks by using a copper net, and grinding if necessary to promote filtration; (d) centrifuging the collected filtrate, separating mononuclear cells, suspending the obtained cells by using a mesenchymal stem cell (MSC) culture medium, and culturing in a 5 percent CO2 incubator at 37DEG C; and (e) after the dispersed cells form clones, selecting the clone cells, respectively culturing by using an MSC culture medium, and after the cells are fused, performing digestion and passage by using pancreatin to obtain the mesenchymal stem cells of the placenta. By the method, high purity mesenchymal stem cells of the placenta can be obtained.

The invention discloses a serum-free medium for culturing placenta mesenchymal stem cells. The serum-free medium takes a DMEM (Dulbecco Modified Eagle Medium) culture solution as a basis and also contains a fibroblast growth factor receptor 2, growth hormone, insulin, transferrin, glutathione, BMP-4, L-glutamine, sodium pyruvate, non-essential amino acids and beta-mercaptoethanol. According to various serum-free media provided by the invention, growth and proliferation of the placenta mesenchymal stem cells in a serum-free medium system can be effectively promoted, the placenta mesenchymal stem cells have higher growth and proliferation rate in the serum-free medium system compared with a serum cell culture medium, the characteristics of the stem cells are preserved, the serum-free medium has multiple differential potentials, and the stem cells can be directionally induced into fat cells and osteoblasts.

The present invention describes stem cells obtained from post-partum placenta and their methods of obtaining and culturing. The present invention also describes compositions comprising placental stem cells and methods of using placental stem cells.

Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclaimpsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin β subunit (hCG-β), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control.

The invention discloses a speckle-removing composition, a preparation method thereof and applications thereof. The speckle-removing composition is prepared from raw materials, by weight, comprising 5-20 parts of saussurea involucrate, 5-20 parts of donkey-hide glue, 5-25 parts of liquorice, 5-25 parts of placenta, 5-20 parts of collagen, 5-20 parts of hyaluronic acid, 5-25 parts of vitamin E, 1-15 parts of vitamin B6, 5-20 parts of oat polypeptides, 5-20 parts of pearl powder, 1-20 parts of aloe, 5-25 parts of safflower, 5-25 parts of white peony roots, 1-20 parts of vitamin C, 5-20 parts of vitamin B3 and 1-15 parts of vitamin B5. The invention provides the speckle-removing composition. The speckle-removing composition has advantages of no irritation; no toxic or side effects; high safety; no hypersensitivity; capability of providing radical cure; good speckle removing effects; low recurrence rate; capability of replenishing nutrition for skin, whitening skin, preserving moisture and repairing skin pits; and capability of making skin smooth, fine, white, clear and wettish. The speckle removing cure rate is 96.7%.

The invention discloses a method for preparing a mesenchymal stem cell by using umbilical cords and placenta, and mainly relates to a new source for the mesenchymal stem cell and a preparation method thereof. The umbilical cord or the placenta is employed by the stem cell as a cell source; tissues are assimilated at first; then a single cell suspension is prepared and inoculated into a culture bottle, a culture dish or a culture bag to amplify the mesenchymal stem cell, then amplified the mesenchymal stem cell is assimilated, collected and frozen. The mesenchymal stem cell prepared according to the technique of the invention contains a plurality of mesenchymal stem cells with excellent multiplication potentiality. The mesenchymal stem cell can be used in the experimental study, clinical treatment and tissue engineering, etc. The material source thereof is abundant; the separation successful rate and yield are high; the cell multiplication capacity is strong; and the contents of allergic and animal-originated substances are low.

Pregnancy-associated glycoproteins (PAGs) are structurally related to the pepsins, thought to be restricted to the hoofed (ungulate) mammals and characterized by being expressed specifically in the outer epithelial cell layer (chorion/trophectoderm) of the placenta. By cloning expressed genes from ovine and bovine placental cDNA libraries, the inventors estimate that cattle, sheep, and most probably all ruminant Artiodactyla, possess possibly 100 or more PAG genes, many of which are placentally expressed. The PAGs are highly diverse in sequence, with regions of hypervariability confined largely to surface-exposed loops. Selected PAG that are products of the i0nvasive binucleate cells, expressed highly in early pregnancy at the time of trophoblast invasion and expressed weakly, if at all, in late gestation are useful in the early diagnosis of pregnancy. In a preferred embodiment, the invention relates to immunoassays for detecting these PAGs.

The invention relates to the technical field of stem cells, in particular to a placenta-derived mesenchymal stem cell freezing medium. The placenta-derived mesenchymal stem cell freezing medium comprises the following components in parts by weight: 40-70 parts of DEME culture medium, 2-6 parts of sodium glycerophosphate solution, 1-5 parts of hydroxyethyl starch, 1-4 parts of mannitol solution, 0.3-0.8 part of ethanediol, 0.5-2 parts of polyvinyl alcohol, 0.5-1.8 parts of trehalose, and 0.5-1.5 parts of polyvinylpyrrolidone. With the adoption of the freezing medium for storing placenta-derived mesenchymal stem cells, the damage on the stem cells in the freezing process can be reduced, and the survival rate of the stem cells after thawing is increased.

The invention discloses medicine for treating milch cow postpartum retention of placenta, which is prepared with the following Chinese traditional medicines in certain weight portions: astragalus, lanceolata, atractylodes, roasted ginger, cinnamon, angelica, rhizome ligustici chuanxiong, salvia, peach kernel, safflower, achyranthes root, olibanum, myrrh, hawthorn and radix auckladiae. The medicine with the invention has 100 percent of effective rate on the treatment of milch cow postpartum retention of placenta, 99 percent of cure rate and significant curative effect; the disease can be cured with the medicine, the curative effect is definite after use, an unserious cow can be cured in one course, a serious cow can be cured in two courses, and one course is one to two days.

The invention discloses a cultivation method for blood-replenishing golden cicadas, and relates to the field of artificial golden cicadas cultivation technologies. The cultivation method comprises the following steps: building a farm, culturing nymph, and planting fodder, wherein the farm is built in a forest of poplar, elm, willow and tung trees or an orchard which has convenience in drainage and irrigation; the land under the trees is ploughed deeply and soil is turned by using an agricultural plow; prepared traditional Chinese medicinal composition is uniformly spread on the land; the soil is smashed by using a rotary cultivator and the land surface is flattened; the traditional Chinese medicinal composition is prepared by the following raw medical materials in part by weight: 5 to 12 parts of placenta hominis, 5 to 12 parts of Chinese date, 5 to 12 parts of lotus seed meat, 20 to 30 parts of shelled melon seed, 20 to 30 parts of longan, 20 to 30 parts of litchi, 10 to 20 parts of walnut, 6 to 13 parts of ginseng, 7 to 11 parts of angelica sinensis, 5 to 8 parts of velvet antler, 6 to 10 parts of ophiopogon japonicus, and 5 to 12 parts of polygonum multiflorum. According to the cultivation method for the blood-replenishing golden cicadas provided by the invention, the growth environment of the golden cicadas is changed by utilizing the traditional Chinese medicinal composition, so that the active ingredients of the traditional Chinese medicinal composition can be absorbed by the golden cicadas under the soil, and the golden cicadas with the efficacy of replenishing blood can be obtained.

The present invention provides methods of cryopreserving stem and progenitor cells in a mammalian placenta; and methods of obtaining fetal stem and progenitor cells from a cryopreserved mammalian placenta. Cells obtained by carrying out the methods can be used in a variety of therapeutic applications.

The invention relates to placenta preserving fluid with pH value of 7.33-7.83; the placenta preserving fluid per 1,000ml contains 10-15mmol of potassium dihydrogen phosphate, 30-40mmol of sodium chloride, 40-50mmol of potassium chloride, 8-10mmol of magnesium sulfate, 70-100mmol of histidine, 1.5-2.0mmol of allopurinol, 3mmol of reduced glutathione, 1-8ml of 2-mercaptoethanol, 8-10mmol of adenosine, 1,000,00-1,000,000U of penicillin, 60-100mg of streptomycin and 50-70mg of gentamicin. The placenta preserving fluid can store the delivered placenta for a long time, prevent from reduction of cell activity and control the bacteria contamination rate of the placenta to be in a low level.

Provided herein are dual modality imaging systems and methods within displayed anatomical structures of placenta in real time. The imaging system comprises a dual modality laser optoacoustic and ultrasonic platform with a plurality of subsystems for delivering near infrared light, optoacoustic and ultrasonic pulses to the placenta and/or associated tissue and deep anatomic structures, for detecting ultrasonic pulses generated or reflected within the tissue using a multi-channel optoacoustic-ultrasound probe and associated transducers. The dual modality imaging system displays the results obtained as quantitative functional images of the parameters coregistered with anatomic tissue images. A multichannel electronic system comprising a computer tangibly storing software enables processor-executable instructions to calculate quantitative functional parameters of the placental blood within specific anatomical tissue structures and display quantitative functional optoacoustic images of the functional parameters within specific anatomical structures in the tissue that are visualized by ultrasound.

The invention provides a coproduction process for extracting various bioactivators from pig placenta, which comprises the following steps: taking the pig placenta (containing farrowing blood) as a raw material, utilizing components rich in the raw material such as immune globulin (Ig), immunocompetent peptide, superoxide dismutase (SOD), lipopolysaccharide, placental protein and the like, and applying modern biochemistry technology and biological integration technology such as salting in, salting out, chromatography, ultra-filtration and the like according to different structures, molecular weights, isoelectric points, physical and chemical properties, biological activities of the components to make the coproduction process suitable for industrial production. Therefore, in the same flow of the production process, the effective components in the pig placenta with market development value can be produced, namely five products of the immune globulin, the immunocompetent peptide, the superoxide dismutase, the lipopolysaccharide and the placental protein. The process combines the conventional and modern processes, produces various products through coproduction, and not only makes full use of placenta resources to change the waste into the treasure, does not discharge waste liquid and prevents the environment, but also can greatly reduce the production cost and improve the economic benefit.